On May 5, 2025, PTC Therapeutics, Inc. announced a conference call to discuss the Phase 2 study results of PTC518 for Huntington’s disease, along with a press release and presentation linked to the event.
AI Assistant
PTC THERAPEUTICS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.